Another FDA recall for Medtronic's HeartWare device

The U.S. Food and Drug Administration issued another Class 1 recall for Medtronic's HeartWare Ventricular Assist Device on Thursday, this time over the risk of battery failure.

Medtronic said it is replacing the affected batteries.

The news comes two weeks after regulators issued a Class 1 recall for a different problem with the HeartWare device. Medtronic discontinued sales of the product in June 2021 after a series of problems surfaced. The FDA issues Class 1 recalls in cases where "use of these devices may cause serious injuries or death."

"Medtronic is investigating a potential welding defect affecting a specific lot of external batteries for the HeartWare Ventricular Assist Device (HVAD) pump," Medtronic spokeswoman Erika Winkels said in a statement. "The issue was initially identified through complaints that the battery has stopped providing power or failed to hold a charge."

According to the FDA, this welding defect could cause a battery to malfunction and possibly suddenly fail. The latest recall affects 429 devices in the U.S., all made during one week in April 2021.

"Medtronic reports one death associated with this recall, and two complaints in the affected lot," according to the FDA's notice.

Medtronic issued an alert May 5 to all patients potentially affected by the battery issue.

Madris Kinard, an expert in medical technology regulations and recalls, said the HeartWare recalls are troubling.

"There are other devices I've seen get recalled very quickly," the CEO of Pennsylvania-based Device Events said. "Why this continues to be an issue is definitely a concern."

Kinard's company makes software that sifts through and analyzes FDA information on adverse events associated with medical devices. Her clients include health care organizations and insurance companies.

The recall earlier this month affected more than 1,600 devices in the U.S. and was due to a welding defect that could cause the pump to rotate incorrectly. The malfunction caused patients to develop symptoms akin to pump thrombosis, which is a blockage of blood flow through a vessel.

Before that recall, about 3,800 patients still had implanted HVAD pumps.

The HVAD device was tailored to patients with severe heart failure; its mechanical pump was designed to increase blood flow through the body.

When Medtronic stopped selling the product last year, it reported receiving more than 100 complaints for the delay or failure to restart the pump. The problem was blamed for 14 deaths.